高级检索
当前位置: 首页 > 详情页

Progesterone suppresses A beta(42)-induced neuroinflammation by enhancing autophagy in astrocytes

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China [2]Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China [3]Department of Pharmacy, Bethune International Peace Hospital, Shijiazhuang, Hebei Province, China
出处:
ISSN:

关键词: Alzheimer Inflammation Astrocyte Progesterone Autophagy

摘要:
Autophagy is an intracellular catabolic mechanism essential for recycling intracellular unfolding protein and eliminating toxic protein aggregates. Several studies have shown that deficient autophagy is implicated in the development of Alzheimer's disease (AD) progression. To date, rapidly emerging evidence suggests that neurosteroid progesterone (PG) may play an important role in ameliorating AD. However, the role of PG and its neuroprotective mechanism in regulating autophagy still require further investigation. Here, we investigated the protective effects of PG against All-induced inflammatory responses in astrocytes and its underlying mechanism in mediating autophagy. Remarkably, AD induced astrocyte dysfunction in autophagic activation and up-regulated inflammatory secretion. However, the autophagy inducer rapamycin (RAPA) significantly suppressed AD induced inflammation in astrocytes. In astrocytes, treatment with AD caused autophagy deficiency, whereas PG significantly increased autophagy activation. Finally, PG suppressed AD-induced neuroinflammatory production via enhancing autophagy together with regulating mTOR signaling. Taken together, these results show that autophagy is a vital mechanism against AD-induced neuroinflammatory responses in astrocytes and demonstrate the potential neuroprotective mechanism of PG in suppressing neuroinflammatory responses by enhancing autophagy. Therefore, uncovering the neuroprotective mechanism of PG may provide new insight into novel therapies for the amelioration of AD.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2018]版:
大类 | 3 区 医学
小类 | 3 区 免疫学 3 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 药学 3 区 免疫学
JCR分区:
出版当年[2018]版:
Q2 IMMUNOLOGY Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China
通讯作者:
通讯机构: [2]Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China [*1]Breast Center, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang, Hebei Province, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号